Gattino (below, right) spent 20 years with Pfizer and served as chief operating officer and regional business director responsible for operational issues in 10 Northern European countries.
He also held the position of country chief executive in Hungary.
The company said in a statement that Gattino had "a strong track record of commercialising drugs and medical devices around the world".
This would help predict asthma attacks. The device syncs to a smartphone and is claimed to be particularly useful to parents with young asthmatic kids.
Gattino last role was as vice-president and general manager (ANZ) for Ikaria, a drug/medical device company, where he turned around the Australia and New Zealand business and spearheaded an expansion into APAC.
Gattino has also been managing director for Perrigo ANZ, a company that makes consumer healthcare products, and was the key adviser to an in-vitro diagnostic start-up where he developed its global commercialisation strategy and successfully raised capital.
Respiri chairman Leon L’Huillier said: “Respiri is very fortunate to attract someone of Mario’s standing. He is ideally suited to lead the company into its commercialisation phase as we look to launch AirSonea in a number of key markets next year. We welcome him to our team.”